Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

S. G. P. Funnell; W. E. Dowling; C. Muñoz-Fontela; P.-S. Gsell; D. E. Ingber; G. A. Hamilton; L. Delang; J. Rocha-Pereira; S. Kaptein; K. H. Dallmeier; J. Neyts; K. Rosenke; E. de Wit; H. Feldmann; P. Maisonnasse; R. Le Grand; M. B. Frieman; C. M. Coleman

doi:10.1038/s41467-020-17907-w

Nature Communications (Aug 2020)

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

S. G. P. Funnell,
W. E. Dowling,
C. Muñoz-Fontela,
P.-S. Gsell,
D. E. Ingber,
G. A. Hamilton,
L. Delang,
J. Rocha-Pereira,
S. Kaptein,
K. H. Dallmeier,
J. Neyts,
K. Rosenke,
E. de Wit,
H. Feldmann,
P. Maisonnasse,
R. Le Grand,
M. B. Frieman,
C. M. Coleman

Affiliations

S. G. P. Funnell: National Infection Service, Public Health England
W. E. Dowling: Coalition for Epidemic Preparedness Innovations
C. Muñoz-Fontela: Bernhard Nocht Institute for Tropical Medicine
P.-S. Gsell: World Health Organisation
D. E. Ingber: Wyss Institute for Biologically Inspired Engineering, Harvard University
G. A. Hamilton: Emulate Inc.
L. Delang: Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute, Global Virus Network, KU Leuven
J. Rocha-Pereira: Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute, Global Virus Network, KU Leuven
S. Kaptein: Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute, Global Virus Network, KU Leuven
K. H. Dallmeier: Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute, Global Virus Network, KU Leuven
J. Neyts: Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute, Global Virus Network, KU Leuven
K. Rosenke: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health
E. de Wit: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health
H. Feldmann: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health
P. Maisonnasse: Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT)
R. Le Grand: Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT)
M. B. Frieman: Department of Microbiology and Immunology, University of Maryland School of Medicine
C. M. Coleman: School of Life Sciences, University of Nottingham, Queen’s Medical Centre

DOI: https://doi.org/10.1038/s41467-020-17907-w
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 4

Abstract

Read online

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal